Neurodegenerative disorders (NDDs) include a heterogenous group of pathologies, with Alzheimer’s disease (AD) being the most frequent, according to present epidemiological data (Cui et al., 2020; Gustavsson et al., 2023). NDDs have some common features that differentiate them from other non-communicable diseases in humans, despite having heterogeneous clinical manifestations, such as predominant motor symptomatology in Parkinson’s disease (Moustafa et al., 2016) or, more important cognitive and behavioral deficits in frontotemporal dementia (Johnen and Bertoux, 2019). NDDs, particularly AD, are a challenge for the clinician because of several reasons: the increasing prevalence in the aging population (Logroscino et al., 2022), the incomplete understanding of the underlining pathophysiology (Wilson et al., 2023), and the absence of an effective or curative treatment despite the immense number of clinical trials conducted in recent years (Mortberg et al., 2022). Because of the lack of effective treatment, one promising first step for ensuring antidementia therapeutic advancements remains the return to basic pathophysiological processes that could explain the onset and evolution of AD (Vaz and Silvestre, 2020; Mehkri et al., 2022). Currently, many debated hypotheses incompletely describe the occurrence of AD; the most acknowledged ones focus on the pathological accumulation of misfolded proteins such as amyloid beta (Aβ) (Karran and De Strooper, 2022), the negative influence of Tau protein hyperphosphorylation (Rawat et al., 2022), the role of ApoE4 and its related protein (Raulin et al., 2022), the negative impact of reactive oxygen species (Bhatt et al., 2021), chronic inflammation involving neurons and glial cells in the central nervous system (CNS) (Xie et al., 2022), and the role of the blood-brain barrier (BBB) disruption in the evolution of the disease (Hussain et al., 2021). A recent approach is based on the role of iron in the healthy brain and the consequences of dysregulated iron metabolism concerning the cellular and molecular dysfunction encountered in AD (Peng et al., 2021). Although the research on this topic is still in its infancy, with many unknowns and incompletely explained mechanisms, this concept could become a linking point for the other accepted theories on neurodegeneration (Spotorno et al., 2020; Ward et al., 2022). Moreover, the “ferroptosis hypothesis of AD” is a valuable source for developing new drugs that might be at least effective adjuvant treatment, if not promising principal therapies (Nikseresht et al., 2019). With growing data on iron pathophysiology in the AD-affected brain and the emergence of novel iron chelation-based therapies, there is a great need to summarize the current knowledge of expanding literature in the field. In this context, this mini-review aims to offer a succinct and practically-oriented overview of the presently available iron chelators used in the clinical areas, with potential interest for AD treatment, and a summary of the theoretical data on iron metabolism. Discussed topics include iron absorption, transport, regulation, and elimination at the CNS level; the relationship between iron metabolism and other pathological processes encountered in AD, such as protein misfolding, inflammation, oxidative stress, and the alteration of the blood-brain barrier; the newer concept of ferroptosis is also covered.

Iron, an essential trace metal in the human body, plays important roles in many physiological processes, such as redox reactions (Koppenol and Hider, 2019), metabolic pathways modulation (Phelan et al., 2018), DNA synthesis and repair (Carter et al., 2022), and mitochondrial energy generation (Onukwufor et al., 2022). These biological processes are possible because of iron’s unique chemical characteristics, especially its ease of maintaining a dynamic balance between the bivalent and the trivalent forms (Yiannikourides and Latunde-Dada, 2019). Further, a clear differentiation between iron homeostasis in the CNS versus the periphery was made to highlight the importance of the BBB as the main boundary between the two distinct compartments. In physiological conditions, there are 3–5 g of iron in the human body (Abbaspour et al., 2014); this constant quantity is provided by two sources, absorption via intestinal cells from food (Fuqua et al., 2012) and release from macrophages (Sukhbaatar and Weichhart, 2018). The complex molecular mechanisms involved in enteral iron absorption are reviewed elsewhere (Gulec et al., 2014). A good understanding of the roles played by the duodenal cytochrome-b-like protein (DCYTB) (Lane et al., 2015) located at the apical side of the intestinal cell or by ferroportin (Nemeth and Ganz, 2021), located at the basal side of the enteric cell, is mandatory to develop therapeutic means which could enhance or limit iron absorption according to individual needs. Once in plasma, iron can bind to transferrin (Gkouvatsos et al., 2012), subsequently fixes to specific membrane receptors, and enters intracellularly via clathrin-mediated endocytosis (Gammella et al., 2021). Two main iron storage compartments exist in the periphery, hepatocytes and macrophages, storing iron mainly in the form of ferritin (Recalcati and Cairo, 2021). Additionally, iron can also be found in the formation of myoglobin (Elkholi et al., 2022), cytochrome (Misslinger et al., 2017), and other iron-regulated enzymes (Poulos, 2014).

An interesting aspect is related to the regulatory mechanisms, with iron regulatory proteins (IRP) as the main players in maintaining intracellular iron homeostasis (Zhang et al., 2014). IRP1 and IRP2 act like iron sensors (Zhang et al., 2014). Still, their activity is also modulated by other molecules, such as oxygen and nitrous oxide (Luo et al., 2011), explaining the tight correlation between iron metabolism and oxidative stress (Cairo and Recalcati, 2007). On the other hand, the liver is a fine regulator of the systemic concentration of iron via the secretion of hepcidin (Vela, 2018), while macrophages are capable of increasing the iron level in the systemic circulation through the phagocytosing of aging red blood cells (Recalcati and Cairo, 2021). Finally, recent studies showed the impact of gut microbiota in modulating iron absorption (Malesza et al., 2022). Besides the direct, local mechanisms of the microbiome, a key role is thought to be also played by the gut-brain axis, with indirect evidence resulting from clinical trials conducted in psychiatric patients (Fernández Real et al., 2019). Knowing in detail the mechanisms that ensure iron homeostasis in humans is of interest from a clinical point of view: genetic diseases remain an important chapter in pathology, with numerous genetic mutations currently known to lead to iron overload syndromes (such as hereditary hemochromatosis) with significant systemic impact (Piperno et al., 2020).

When studying iron absorption at the CNS level, mechanisms are similar to the gastrointestinal endothelial tissue. However, the endothelial layer forming the wall of the cerebral blood vessels has some particularities. The BBB, a unique and highly selective structure in the human brain (Alahmari, 2021), is responsible for ensuring the protection of the sensitive cerebral tissue against external toxic factors (Pandit et al., 2020), meaning that free circulating and transferrin-bound iron must pass via the brain microvascular endothelial cell (BMEC) by specific mechanisms. Several explanations can be found in the literature, The roles of ferroportin 1 (Mezzanotte et al., 2022), ceruloplasmin (Ryan et al., 2019), hephaestin (Zacchi et al., 2021), and holo-transferrin (Baringer et al., 2022) have been proposed to explain iron-transferrin complex internalization, while free, unbound iron is suspected to enter the neuron via transcytosis, after binding to heavy-chain ferritin (H-ferritin) (Mesquita et al., 2020) or lactoferrin (Kell et al., 2020).

The intraneuronal metabolism of iron is not significantly different from the metabolism of other cells found in the periphery; however, there should be noted an overexpression of transferrin 1 receptors on the surface of the neurons (Menon et al., 2019) and an increased age-dependent cerebral level of ferritin (Ficiarà et al., 2022). Moreover, besides neurons, glial cells and microglia are also involved in regulating iron cerebral levels (Xu et al., 2018), ensuring neural protection against iron toxicity (Nnah and Wessling-Resnick, 2018). Iron is involved in the myelination of oligodendrocytes, the most iron-rich cells in the brain (Khattar et al., 2021), this finding being additional proof of the multitude of physiological roles iron exerts at the CNS level.

Although the pathological accumulation of misfolded proteins is thought to be the central feature of AD pathogenesis, alterations in iron homeostasis with subsequent iron accumulation should also be considered as the driver of AD pathology (Liu et al., 2018). Proof for this new research direction is the multitude of studies that have demonstrated abnormally high levels of iron in key brain regions, such as the hippocampus or the frontal cortex, beginning with the preclinical stages of AD (Tran et al., 2022; Lin et al., 2023). Additionally, the cerebral iron load was correlated with the severity of the symptoms (especially cognitive deficit) (Spence et al., 2020); it was also considered a reliable predictor of the evolution of the disease (Ayton et al., 2020a).

Several hypotheses try to explain iron dyshomeostasis in AD. Firstly, the close interaction with amyloid plaques and neurofibrillary tangles should be noted (Liu et al., 2018; Wang et al., 2022). On the one hand, the anatomopathological (Tran et al., 2022) and imaging studies (Gong L. et al., 2019) showed an increased concentration of iron in the areas rich in Aβ accumulations and also in cortical areas rich in Tau protein accumulations. On the other hand, the disruption of the normal iron metabolism at the cerebral level, with the alteration of IRP, supports the amyloid cascade by upregulating amyloid precursor protein (APP) and by modulating alpha and beta-secretases, two key enzymes involved in APP degradation (Gong N. J. et al., 2019). However, there is no proof up to the present of a direct impact of iron accumulation on senile plaque formation. It seems that iron accumulation occurs concomitantly with amyloid accumulation in the brain as two synergic processes that lead to neurodegeneration (Peters et al., 2015). It remains to be determined if iron imbalance precedes and could trigger senile plaque formation. Regarding the effect of iron dyshomeostasis on Tau hyperphosphorylation, a direct correlation was observed between increased iron intake, cognitive deficit, and abnormal accumulation of Tau protein, with insulin signaling as the main molecular mechanism (Wan et al., 2019).

However, the impact of iron at the brain level is much more closely related to oxidative stress, as iron is an essential factor in numerous redox reactions resulting in the generation of reactive oxygen species (ROS) (Zhang et al., 2022). At the same time, excess iron reduces antioxidant mechanisms, ultimately leading to ferroptosis and neuronal loss (Mancardi et al., 2021). Ferroptosis, a type of programmed cell death first described in 2012 (Dixon et al., 2012), involves lipid peroxidation generated by the iron overload, leading to cell swelling, mitochondrial dysfunction, nuclear chromatin condensation, and, finally, cellular membrane rupture (Han et al., 2020). Various studies have shown a correlation between the accumulation of iron in the brain which means increased ferroptosis and aging (Coradduzza et al., 2023), cerebrovascular diseases (Liu et al., 2022), and neurodegenerative diseases (including AD) (Ma et al., 2022). However, the exact molecular mechanisms of iron-induced neurodegeneration remain incompletely known. Recent research focused mainly on the roles of glutathione peroxidase 4 (GPX4) (Cardoso et al., 2017) and glutamate/cystine antiporter (xCT) (Lane and Lin, 2023) in the pathogenesis of AD in both animal models and humans, an overview of the currently accepted mechanism being schematized in the work of Wang et al., 2022.

Finally, iron can also lead to neurodegeneration by regulating glial cells, more precisely by activating microglia (Long et al., 2022) and astrocytes (Codazzi et al., 2015). Microglia are strongly reactive to iron exposure, and, when activated, they produce pro-inflammatory cytokines, thus facilitating the accumulation of Aβ (Cai et al., 2022). Moreover, activated microglia support the additional accumulation of iron in the brain through a positive feedback mechanism (Kenkhuis et al., 2021). On the other hand, in the first phases of inflammation, astrocytes are less reactive compared to neurons or microglia; however, in the later stages, astrocytes also generate inflammatory mediators, subsequently supporting oxidative stress, the chronic inflammatory status, and the pathological accumulation of misfolded proteins such as Tau and Aβ (Monterey et al., 2021). Astrocyte activation by pathological iron accumulation is an indirect link between iron and the BBB, as chronic neuroinflammation leads to BBB disruption, which means increased permeability and sustained neuronal damage. Yet, the astrocyte-heavy metal link is bidirectional, with astrocytes demonstrated to control iron and other metal ions concentration in the brain parenchyma via specific transporters (Li et al., 2021). This also explains why astrocyte dysfunction is strongly related to cerebral iron imbalance in neurodegenerative disorders, including AD.

With increasing evidence related to the role of iron in the pathogenesis of AD, iron chelation could be a potentially effective therapeutic approach. This therapy is already successfully used in iron overload syndromes such as sickle cell disease, major beta-thalassemia, and rare disorders of iron-transporting proteins (Bruzzese et al., 2023). In this context, there are drugs approved for daily clinical use, their relevant characteristics being summarized in Table 1.

Deferoxamine (DFO) is the most well-known iron chelator, with more than 3 decades of clinical experience (Parker et al., 2023). However, the visual and ototoxicity (Derin et al., 2017) and potentially decreased compliance due to the subcutaneous/intravenous administration protocol (Yarali et al., 2006) opened the pathway for developing newer drugs. Deferasirox (DFX) and deferiprone (DFP) are two orally administered iron chelators that are more patient-friendly regarding the potential side effects (Entezari et al., 2022). However, higher costs for DFX and weekly blood monitoring in the case of DFP can limit their use (Ravalli et al., 2022). Finally, there is also the possibility to administer the abovementioned drugs in combination, however, despite being safe for patients, the exact benefits of this approach are incompletely studied (Origa et al., 2022).

Besides the already approved drugs, increasing research is conducted on novel therapeutic alternatives. Hydroxybenzyl ethylenediamine (HBED) has been longly proposed as a potential iron chelator (Samuni et al., 2001), but apart from a few incipient studies, the lack of sufficient data prevented its approval for routine clinical use. Ascorbic acid (vitamin C) is another relevant compound intensely studied in the last years, both because ascorbic acid is directly involved in redox reaction modulation and because the interaction between vitamin C and iron modulates many metabolic pathways (Kontoghiorghes et al., 2020). The main limitation is related to the weak capacity of vitamin C in chelating iron, having a low efficacy in iron elimination, and explaining why vitamin C is mainly recommended as adjunctive therapy (Elalfy et al., 2016).

Some compounds/drugs, initially designed to act on different molecular pathways, demonstrated also an effective iron-chelation feature. One good example is clioquinol, an antifungal and antiprotozoal drug, that demonstrated iron chelation characteristics in several conditions, such as pulmonary fibrosis (Zhu et al., 2021), Parkinson’s disease and AD (Nuñez and Chana-Cuevas, 2018). Similarly, antioxidant medications such as vitamin E, alpha-lipoic acid, and selenium are thought to interact indirectly with iron metabolism and could be potentially effective in treating AD.

Another group of potential adjuvant agents for iron depletion is represented by calcium channel blockers. The explanatory pathophysiologic mechanism is based on the blocking of the penetration of iron through calcium channels at the level of the heart, pancreas, and other organs, consequently possible prevention of visceral iron accumulation (Sun et al., 2020). A systematic review (Sadaf et al., 2018) highlighted the main reasons calcium channel blockers are still under scrutiny and not approved for clinical use: lack of sufficient clinical trials, no significant iron level reduction in organs and blood, and insufficient proof of safety. Thus, there is a high demand for new, larger randomized clinical trials to confirm the benefit of the abovementioned proposed iron chelating therapies.

Finally, apart from iron, other trace elements, such as copper, calcium, and zinc, seem to play relevant roles in CNS homeostasis and the pathophysiology of AD (Wang and Wang, 2017). Despite contradictory studies and many incompletely elucidated mechanisms, copper could become a valuable target for anti-dementia therapies (Ejaz et al., 2020). Moreover, future research should assess if any relevant link between iron and other trace elements exists and its impact on neurodegeneration.

NDDs, particularly AD, represent an important burden worldwide, and with prevalence expected to sustainably grow in the next decades, the development of effective therapies is essential. The incomplete understanding of its etiology remains one of the main reasons for the slow therapeutic advancements for AD. The emergence during the last years of new hypotheses, complementary to the already established knowledge, should be noted, with the “ferroptosis hypothesis of AD” one good example.

Besides the important theoretical input, new theories related to AD pathogenesis are also valuable sources for new therapeutic approaches which might prove effective.

In this regard, iron chelators could be successfully used in AD treatment, as there are already three compounds approved for clinical use in patients with iron overload syndromes. Moreover, the possibility of using adjuvant therapies such as vitamin C or calcium channel blockers, and antioxidants such as vitamin E or alpha-lipoic acid, if proven efficient and safe, opens new perspectives for AD patients. At present, iron chelation in AD management remains an open topic, with only a few trials available. Worth to be mentioned is an old trial dating back to 1991, when intramuscularly chronically administered DFO (24 months, 5 days/week), showed a decrease in AD progression compared to the control group (Crapper McLachlan et al., 1991). Up to the present, no other randomized clinical trial on humans has delivered significant results, but we mention one notable, still-in-progress trial, that analyzes the effects of DFP in AD patients (Ayton et al., 2020b). Regarding DFX, only trials on animal models can be found when searching the literature (Kwan et al., 2022). With increasing theoretical background sustaining the impact of iron in AD pathogenesis, iron chelation should be more intensely studied as main or adjuvant therapy, in patients in different AD stages.